Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829522 | 1.00 | ALDH1A1 (0.35) | ALDH1A1USP30GRM1AAK1PROKR1 | |
| SCHEMBL828105 | 0.92 | ALDH1A1 (0.34) | ALDH1A1AAK1PROKR1SSTR4 | |
| SCHEMBL829243 | 0.92 | ALDH1A1 (0.34) | ALDH1A1AAK1PROKR1SSTR4 | |
| SCHEMBL829906 | 0.91 | SSTR4 (0.33) | ALDH1A1AAK1SSTR4 | |
| SCHEMBL828285 | 0.91 | SSTR4 (0.33) | ALDH1A1AAK1SSTR4 | |
| SCHEMBL828686 | 0.89 | ALDH1A1 (0.38) | ALDH1A1AAK1PROKR1KDM5AKDM4C | |
| SCHEMBL830914 | 0.89 | ALDH1A1 (0.38) | ALDH1A1AAK1PROKR1KDM5AKDM4C | |
| SCHEMBL828825 | 0.87 | PROKR1 (0.35) | ALDH1A1USP30GRM1AAK1PROKR1 | |
| SCHEMBL828699 | 0.87 | PROKR1 (0.35) | ALDH1A1USP30GRM1AAK1PROKR1 | |
| SCHEMBL829402 | 0.85 | AAK1 (0.34) | ALDH1A1AAK1PROKR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | ALDH1A1 4439/4885USP30 1327/4885GRM1 1855/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | ALDH1A1 4439/4885USP30 1327/4885GRM1 1855/4885 |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | ALDH1A1 1127/4885USP30 3042/4885GRM1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.